Trial Profile
An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jun 2022
Price :
$35
*
At a glance
- Drugs Sym 015 (Primary)
- Indications Gastric cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Symphogen
- 12 Jan 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Interim safety and efficacy results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 16 Jan 2020 Planned End Date changed from 1 Sep 2020 to 1 Oct 2020.